• Today
    July 07

  • 11:22 AM

WHO suspends testing malaria drug in COVID-19 patients

REUTERS,

Added 26 May 2020

hydroxychloroquine

Hydroxychloroquine (Reuters)

GENEVA – The World Health Organisation (WHO) has suspended testing the malaria drug hydroxychloroquine in COVID-19 patients due to safety concerns, Director General Tedros Adhanom Ghebreyesus said on Monday.

Hydroxycholoroquine has been touted by Donald Trump and others as a possible treatment for the disease caused by the novel coronavirus. The U.S. President has said he was taking the drug to help prevent infection.

“The executive group has implemented a temporary pause of the hydroxychloroquine arm within the Solidarity trial while the safety data is reviewed by the data safety monitoring board,” Tedros told an online briefing.

He said the other arms of the trial – a major international initiative to hold clinical tests of potential treatments for the virus – were continuing.

The WHO has previously recommended against using hydroxychloroquine to treat or prevent coronavirus infections, except as part of clinical trials.

Dr Mike Ryan, head of the WHO emergencies programme, said the decision to suspend trials of hydroxychloroquine had been taken out of “an abundance of caution”. (Reuters)

JOIN THE DISCUSSION

Dos and Donts


Welcome to our discussion forum here on nationnews.com. We encourage lively debate, but we also urge you to take note of the following:

  • Stay on topic – This helps keep the thread focused on the discussion at hand. If you would like to discuss another topic, look for a relevant article.
  • Be respectful – Meeting differences of opinion with civil discussion encourages multiple perspectives and a positive commenting environment.
  • Do not type in capitals – In addition to being considered “shouting” it is also difficult to read.
  • All comments will be moderated – Given the volume of comments each day, this may take some time. So please be patient.
  • We reserve the right to remove comments – Comments that we find to be abusive, spam, libellous, hateful, off-topic or harassing may be removed.
  • Reproduction of comments – Some of your comments may be reproduced on the website or in our daily newspapers. We will use the handle, not your email address.
  • Do not advertise – Please contact our Advertising Department.
  • Contact our Online Editor if you have questions or concerns.
  • Read our full Commenting Policy and Terms of Use.
comments powered by Disqus

POLL

Should the headquarters of a new regional airline remain in Antigua & Barbuda?

Yes
No

FRONT COVER OF TODAY'S NEWSPAPER

CARTOON

INSTAGRAM